Introduction
Non-nucleoside reverse transcriptase inhibitors (NNRTI) form the backbone of the three-drug first line regimen against human immunodeficiency virus (HIV) infection in most parts of the world (1) . It has been effectively used in the developing world for a long time owing to their low cost and high potency. In the World Health Organization (WHO) guidelines (antiretroviral therapy for HIV infection in adults and adolescents) published in 2010, both nevirapine and efavirenz were mentioned as preferred NNRTIs for the first line therapy (2) . However, nevirapine slowly fell out of favor because of higher incidence of serious adverse events in early part of therapy, especially in individuals with higher CD4 counts (3) . Therefore, in the WHO consolidated guidelines (Use of antiretroviral drugs for treating and preventing HIV infections) of 2013, efavirenz containing regimens were preferred as the first line therapy while nevirapine based regimens were moved to the alternative first line list (4). However, the question of shifting those patients, who were already on long term nevirapine based therapy to efavirenz containing regimens was still unanswered. The primary objective of this study was to therefore, compare the long-term tolerability of patients receiving nevirapine based regimen vs those receiving efavirenz based regimens.
Methods
A cross-sectional study was conducted after taking approval from the Institute's Ethics committee. Adult patients (> 18 years) on NNRTI based regimens for
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Results and Discussion
A total of 244 patients were recruited in the study, 68% (165) of whom were male. A total of 125 (51%) patients were receiving nevirapine based regimen while 119 (49%) were receiving efavirenz based regimen. Out of the 125 patients receiving nevirapine, zidovudine and lamivudine formed the rest of the regimen in 117 (94%) patients. Out of the 119 patients receiving efavirenz, 108 (91%) patients were also receiving tenofovir plus lamivudine. The patients were also classified into the following groups based on the year of initiation (2005-2008-40, 2009-2012-63, 2013-2017-141) . Median baseline CD4 count at the time of initiation of treatment was 214.5/μL (121-320.5). Median highest CD4 count achieved during treatment was 591.5/μL (413.5-789.5). Median highest increase in CD4 count from the baseline was 362.5/μL (207.25-546.75). Immunological failure was noted in 12 patients. A total of 19 patients had a history of concurrent tuberculosis with HIV. A total of 33 (13.5%) patients reported some clinical side effect during the interview. None of them were severe enough to require discontinuation. The following clinical side effects were reported by the patients: neuropsychiatric symptoms (n = 13), gastro-intestinal symptoms (n = 8), lipodystrophy (n = 5), peripheral neuropathy (n = 3), rash (n = 2) and gynecomastia (n = 2).
The following hematological abnormalities were noted: anemia (< 11g/dL) -41, leucopenia (< 4,000/mm3)-13, leukocytosis (> 11,000/mm3)-7, thrombocytopenia (< 1,000,000/mm3)-34, and macrocytosis (> 100fl)-132. The following biochemical abnormalities were noted: transaminitis-69, deranged kidney function-4, hypophosphatemia (< 2.5mg/dL)-53 and hypocalcaemia (< 8.8mg/dL)-74.
There was no significant difference between the nevirapine and efavirenz group in the following demographic features: locality, distance of home from the ART center, literacy, employment status, addictions and baseline CD4 count (Table 1 ). However, there was significant difference between the two groups in terms of mean age at the time of analysis and year of initiation. There was no significant difference in the frequency of hematological and biochemical derangements except for that of macrocytosis which was more common in the nevirapine group. There was no difference in the median highest CD4 count achieved during therapy but the median of highest change in CD4 count was significantly higher in the nevirapine group. Clinically observed side effects were more common with efavirenz ( Table 1) .
The treatment options for AIDS has drastically changed since 1987, when the first drug, zidovudine was approved (5). Although zidovudine was efficacious, it had serious side effects like bone marrow suppression. Also, monotherapy was eventually leading to resistance and failure. Since then, the world has moved on to effective combination therapy, commonly consisting of three drugs (6) . Two of these drugs are Nucleoside Reverse Transcriptase Inhibitor (NRTI), while the third drug can be either an Integrase inhibitor (INSTI) or Protease inhibitor (PI) or Non-nucleoside reverse transcriptase inhibitor (6) . The Department of Human and Health Services (DHHS) favors an integrase inhibitor based regimen because of its high barrier to resistance, high potency and less side effects (7). However, WHO and national guidelines in India still recommend a NNRTI based regimen owing to their lower cost. Although, NNRTIs have been associated with some side effects (Nevirapine-severe hypersensitivity, Efavirenz-central nervous system (CNS) side effects), most of them are observed in the initial few weeks to months after the initiation of treatment (8) . Both the drugs have shown to have lower frequency of side effects in patients who have been on these drugs for long durations. In our study, a total of only 13.5% patients had clinically observed side effects at the time of interview. This included side effects related to both NRTIs and NNRTIs. None of the side effects were severe enough to require discontinuation. However, clinical observed side effects, predominantly persistent neuropsychiatric symptoms were observed www.ddtjournal.com Drug Discoveries & Therapeutics. 2018; 12(5) :295-298.
of virological success and progression to AIDS (10) . Studies from India have shown good tolerability with both nevirapine and efavirenz (11) (12) (13) (14) .
In conclusion, since most serious adverse events associated with nevirapine are seen during the first few weeks/months of the therapy, nevirapine might be as good as efavirenz, if not better, in those patients who are tolerating it well for years. There isn't enough evidence for shifting the patients on long term nevirapine based therapy to efavirenz containing regimen.
Limitations of the study: This was a cross-sectional study without any follow up and the data was collected from a single interview. more in the efavirenz group.
No significant difference in hematological and biochemical derangements were observed between the two groups except for that of higher frequency of macrocytosis in the nevirapine group. This was because nevirapine was co-administered with zidovudine in 94% of cases, which competes with deoxy nucleoside triphosphates and results in impaired synthesis of the erythrocyte precursor in the bone marrow (9) .
In our study, although we did not find any difference between the highest CD4 count attained during treatment between the two groups, there was a higher median CD4 count change (between baseline and highest) in the nevirapine group. This was probably due to the longer duration of treatment in the nevirapine group. In a meta-analysis by Cochrane infectious diseases group, no significant difference was observed between nevirapine and efavirenz in terms 
